AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for cAMP-specific 3',5'-cyclic phosphodiesterase 4A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P27815

UPID:

PDE4A_HUMAN

Alternative names:

DPDE2; PDE46

Alternative UPACC:

P27815; O75522; O76092; Q16255; Q16691; Q5DM53; Q6PMT2; Q8IVA7; Q8WUQ3; Q9H3H2

Background:

The cAMP-specific 3',5'-cyclic phosphodiesterase 4A, known by its alternative names DPDE2 and PDE46, plays a crucial role in cellular processes by hydrolyzing the second messenger 3',5'-cyclic AMP (cAMP). This enzyme's activity is pivotal in regulating various physiological functions, as it efficiently breaks down cAMP without being influenced by calcium, calmodulin, or cyclic GMP (cGMP) levels.

Therapeutic significance:

Understanding the role of cAMP-specific 3',5'-cyclic phosphodiesterase 4A could open doors to potential therapeutic strategies. Its central function in modulating cAMP levels makes it a compelling target for drug discovery, aiming to manipulate cellular signaling pathways for therapeutic benefits.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.